Activity

EEG studies investigating the effects of psychosocial stressors (PSSs) on neural activity have seen a rise in popularity recently, but the results are frequently obscured by the variability of stressor types. We evaluated the impact of PSSs on neural activity using a paradigm that exposed participants to negative peer comparisons as a form of PSS, with other potential stressors held constant, and compared this with a condition featuring neutral feedback. Evaluating commonly used sensor-level EEG indices (frontal theta, alpha, and beta power), we investigated whether measures of source-level power and functional connectivity (the temporal correlations between spatially separated brain regions), novel to this study, could show greater sensitivity to PSSs than the existing sensor-level EEG metrics. Analysis at the sensor level indicates no significant changes in frontal power (all p-values greater than 0.16), thus implying that sensor-level frontal power measurements are not responsive to PSS effects alone. Analysis at the source level reveals an augmentation of alpha power (suggesting reduced cortical activity) within the left and right precuneus, and the right posterior cingulate cortex (all p-values below 0.003). Concomitantly, functional connectivity between the left and right precuneus is heightened (p-value below 0.0001). This pattern indicates that acute, trial-based PSSs decrease precuneus/PCC activity and possibly points to a transient impairment of the individual’s self-referential neural processes.

Among the most impactful yet modifiable factors affecting both climate change and chronic diseases are individual health-related behaviors. Encouraging actions that create environmental and health co-benefits depends on understanding the foundational elements contributing to behavioral shifts towards a healthy and sustainable way of life. Potential convergence can be found in the general awareness people have about their health. To determine the nature of the relationship existing between health-oriented perspectives and eco-friendly behaviors was the focus of this research effort. Our research explored a potential correlation between concern for health and five types of pro-environmental practices—sustainable food consumption, recycling, green purchasing, sustainable transportation, and energy conservation. Through a cross-sectional survey, a representative sample of 1011 Italian citizens provided the necessary research data. Significant statistical disparities surfaced in the frequency of different pro-environmental actions undertaken by Italians. Their most common sustainable behaviors were linked to energy conservation and waste management (recycling), contrasted by the lowest adoption rate concerning sustainable transportation. The stepwise linear regression model, in addition, exhibited a predictive relationship between citizens’ health consciousness and the adoption of specific types of pro-environmental behaviors, illustrating that a heightened focus on one’s health contributes to stronger pro-environmental engagements. Complex programs integrating educational, awareness-building, and structural elements are crucial, as demonstrated by these results, for motivating citizens to actively participate in public health and pro-environmental endeavors.

The emergence of olfactory dysfunction (OD), a frequent non-motor symptom in Parkinson’s disease (PD), serves as a key prodromal indicator, often appearing years prior to the development of motor symptoms. MicroRNA (miRNA) biomarkers for Parkinson’s Disease (PD) have been consistently observed in ongoing research, however, robust miRNAs as indicators for other disorders (OD) in PD are currently absent.

Concordantly differentially expressed microRNAs (DE miRNAs) in the damaged olfactory system were initially discovered in two Gene Expression Omnibus (GEO) datasets linked to olfactory-related issues. A different GEO dataset pertaining to PD further validated the findings, demonstrating only miR-20a to be significantly altered. The serum levels of miR-20a were further investigated using quantitative PCR (qPCR) in three groups, namely 79 Parkinson’s disease patients with oculomotor dysfunction (PD-OD), 52 Parkinson’s disease patients without oculomotor dysfunction (PD-NOD), and 52 healthy controls (HC). The 16-item Sniffin’ Sticks odor identification test was used to objectively quantify olfactory dysfunction (OD). A clinical assessment concerning Parkinson’s Disease and demographics was performed on all participants.

Our research demonstrated a significant reduction in miR-20a levels in PD-OD specimens compared to PD-NOD specimens. The area under the curve (AUC) for detecting OD using miR-20a was 0.803 (95% confidence interval, 0.724-0.883). PD-OD patients manifested significantly higher scores on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (UPDRS) II, Hoehn and Yahr stage (H-Y), Non-Motor Symptoms Scale (NMSS) 3, NMSS 5, NMSS 9, Hamilton Rating Scale for Depression (HAMD), Hamilton Anxiety Scale (HAMA), and Activity of Daily Living (ADL) scales, coupled with lower scores on the Mini-Mental State Examination (MMSE) and the 39-item Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), compared with PD-NOD patients. According to the binary regression model, lower miR-20a expression and poorer cognitive function were found to be promoting factors in the development of OD.

Our investigation reveals miR-20a as a possible novel biomarker for OD in PD, with PD-OD patients demonstrating a greater disease severity, poorer motor skills affecting daily life, diminished cognitive performance, a reduced quality of life, and a higher risk of mental health conditions. Cognitive function, in particular, demonstrates a strong correlation with OD in Parkinson’s disease patients.

From our study, miR-20a appears as a possible new biomarker for OD in PD. Patients with PD-OD demonstrate more severe disease stages, inferior motor skills in daily tasks, lower cognitive assessments, reduced quality of life, and a higher rate of mental health concerns. OD in PD patients exhibits a considerable association with cognitive function, in particular.

Parkinson’s disease (PD), an incurable movement disorder, is characterized by the loss of dopaminergic cells, neuroinflammation, and alpha-synuclein pathology. A subacute 1-methyl-4-phenyl-12,36-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease was used to evaluate the therapeutic effects of necrosulfonamide (NSA), a specific inhibitor of mixed lineage kinase domain-like protein (MLKL). az628 inhibitor Necroptosis, a programmed cell death pathway characterized by inflammation, is executed by MLKL. Impaired motor performance and dopaminergic degeneration were mitigated by the repeated application of NSA. Furthermore, the phosphorylation, ubiquitination, and oligomerization of MLKL were suppressed by NSA, each of which is associated with MLKL’s cell death-inducing action within the dopaminergic cells of the substantia nigra (SN). NSA not only prevented microglial activation and reactive astrogliosis but also curbed the MPTP-stimulated expression of pro-inflammatory molecules such as TNF-, IL-1, iNOS, and cystatin F. Concluding, NSA’s impact on Parkinson’s disease pathology involves demonstrably anti-necroptotic, anti-inflammatory, and anti-synucleinopathic properties. Consequently, the potential therapeutic value of NSA in PD is evident.

The potency assay displays a Goldilocks-style characteristic. A comprehensive evaluation of the cell product, involving detailed quantitative measurement of the critical quality attributes directly impacting the intended biological activity, is indispensable. In contrast, the potency assay gains from simplified methods and lean principles, which minimize complexities and enhance reliability for a reproducible and scalable product outcome. To create a trustworthy and cost-effective advanced therapeutic medicinal product (ATMP), a straightforward production method should complement a deep understanding of the intricate biological healing processes. Having examined the numerous obstacles to potency assay accuracy in earlier chapters, this chapter instead presents a forward-looking perspective on the recent breakthroughs in acellular products, cryopreservation, induced MSCs, cell priming, nanotechnology applications, three-dimensional cell culture, regulatory guidelines, and institutional changes, which are anticipated to foster future potency assay development.

Investigational pharmaceutical product potency assays, crucial for efficacy assessments, require rigorous monitoring during advanced therapy medicinal product (ATMP) development. The importance of reliable potency assays for stem cell-based advanced therapies is indisputable for achieving safety and effectiveness in clinical settings. Stem cell-based advanced therapies, given their complex and heterogeneous nature, introduce a range of specific challenges in developing appropriate potency assays, encompassing obstacles that span intrinsic limitations and practical considerations to legal and regulatory frameworks. The EU’s regulatory framework for advanced therapies is discussed in this chapter, with a focus on key considerations integral to the formulation of a strategic plan that will meet EU regulatory demands.

Manipulating genes, cells, and tissues to create unique medicinal entities forms the basis of advanced therapy medicinal products (ATMPs), a cutting-edge class of drugs with customized pharmacological properties. Creating adequate potency testing criteria for product release is challenging in this instance, as the active ingredient is comprised of living cells and the precise mechanism of action remains frequently unclear. Potency assessments employed in the release of representative commercial advanced therapies (ATMPs), specifically KYMRIAH (tisagenlecleucel), Holoclar (limbal epithelial stem cells), and PROCHYMAL/RYONCIL (remestemcel-L), are scrutinized and discussed in this chapter. We also evaluate the biological pertinence of selected potency assays, and the challenges for harmonization and widespread application, which must align with current quality standards and regulatory frameworks.